MX2007007259A - Inhibidores de homodimerizacion de myd88. - Google Patents
Inhibidores de homodimerizacion de myd88.Info
- Publication number
- MX2007007259A MX2007007259A MX2007007259A MX2007007259A MX2007007259A MX 2007007259 A MX2007007259 A MX 2007007259A MX 2007007259 A MX2007007259 A MX 2007007259A MX 2007007259 A MX2007007259 A MX 2007007259A MX 2007007259 A MX2007007259 A MX 2007007259A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- myd88
- present
- compounds
- myd88 homodimerization
- Prior art date
Links
- 101150053046 MYD88 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 abstract 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04425929 | 2004-12-20 | ||
| PCT/EP2005/056847 WO2006067091A1 (en) | 2004-12-20 | 2005-12-16 | Myd88 homodimerization inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007007259A true MX2007007259A (es) | 2007-08-14 |
Family
ID=34932941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007007259A MX2007007259A (es) | 2004-12-20 | 2005-12-16 | Inhibidores de homodimerizacion de myd88. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080064643A1 (enExample) |
| EP (1) | EP1828246A1 (enExample) |
| JP (1) | JP2008524167A (enExample) |
| KR (1) | KR20070094802A (enExample) |
| CN (1) | CN101084240A (enExample) |
| AU (1) | AU2005318226A1 (enExample) |
| BR (1) | BRPI0519148A2 (enExample) |
| CA (1) | CA2590750A1 (enExample) |
| MX (1) | MX2007007259A (enExample) |
| WO (1) | WO2006067091A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| CN101745094A (zh) * | 2010-01-28 | 2010-06-23 | 华中科技大学同济医学院附属同济医院 | MyD88拓扑类肽化合物作为免疫抑制剂在医学上的用途 |
| WO2012047175A1 (en) | 2010-10-05 | 2012-04-12 | Kemijski inštitut | Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling |
| CN102336720B (zh) | 2011-03-02 | 2016-01-13 | 华中科技大学 | 2-氨基噻唑衍生物及制备方法和应用 |
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| JP6313203B2 (ja) * | 2011-07-18 | 2018-04-18 | ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｋｅｎｔｕｃｋｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤 |
| EP2561873A1 (de) * | 2011-08-26 | 2013-02-27 | Forschungsverbund Berlin e.V. | Strukturmimetika prolinreicher Peptide und ihre Verwendung |
| US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| WO2013112834A1 (en) * | 2012-01-25 | 2013-08-01 | Vanderbilt University | Compositions and methods for treating infections |
| EP2847215A1 (en) * | 2012-05-07 | 2015-03-18 | Synthes GmbH | Methods and devices for treating intervertebral disc disease |
| CA3113959A1 (en) * | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| CA2930326C (en) | 2013-12-06 | 2022-09-06 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2016092069A1 (de) | 2014-12-11 | 2016-06-16 | Forschungsverbund Berlin E.V. | Inhibitoren zur hemmung der tumormetastasierung |
| JP2019069905A (ja) * | 2016-02-29 | 2019-05-09 | 国立大学法人大阪大学 | 組織損傷治療剤 |
| JP2019518006A (ja) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ |
| CN109415413A (zh) | 2016-06-07 | 2019-03-01 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 髓样分化因子88(myd88)的主链环化抑制肽 |
| BR112020004555A2 (pt) | 2017-09-07 | 2020-09-24 | Fog Pharmaceuticals, Inc. | agentes que modulam funções de beta-catenina e métodos dos mesmos |
| ES3023183T3 (en) * | 2018-01-02 | 2025-05-30 | Univ Rush Medical Center | Compositions and methods for treating neurological and other disorders |
| US12679842B2 (en) | 2019-10-08 | 2026-07-14 | Dana-Farber Cancer Institute, Inc. | HCK as a therapeutic target in MYD88 mutated diseases |
| CN114746095B (zh) | 2019-10-08 | 2025-01-24 | 达纳-法伯癌症研究所有限公司 | Hck作为myd88突变疾病的治疗靶点 |
| WO2024096677A1 (ko) * | 2022-11-03 | 2024-05-10 | 한국과학기술연구원 | Tlr 신호 억제 펩타이드 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2446458A1 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
| US20030148986A1 (en) * | 2001-12-17 | 2003-08-07 | Cedars-Sinai Medical Center | Methods for treating vascular disease by inhibiting myeloid differentiation factor 88 |
-
2005
- 2005-12-16 CA CA002590750A patent/CA2590750A1/en not_active Abandoned
- 2005-12-16 US US11/793,516 patent/US20080064643A1/en not_active Abandoned
- 2005-12-16 KR KR1020077016815A patent/KR20070094802A/ko not_active Withdrawn
- 2005-12-16 JP JP2007546073A patent/JP2008524167A/ja not_active Withdrawn
- 2005-12-16 BR BRPI0519148-3A patent/BRPI0519148A2/pt not_active IP Right Cessation
- 2005-12-16 EP EP05823931A patent/EP1828246A1/en not_active Withdrawn
- 2005-12-16 MX MX2007007259A patent/MX2007007259A/es not_active Application Discontinuation
- 2005-12-16 WO PCT/EP2005/056847 patent/WO2006067091A1/en not_active Ceased
- 2005-12-16 CN CNA2005800437629A patent/CN101084240A/zh active Pending
- 2005-12-16 AU AU2005318226A patent/AU2005318226A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1828246A1 (en) | 2007-09-05 |
| CA2590750A1 (en) | 2006-06-29 |
| AU2005318226A1 (en) | 2006-06-29 |
| US20080064643A1 (en) | 2008-03-13 |
| CN101084240A (zh) | 2007-12-05 |
| WO2006067091A1 (en) | 2006-06-29 |
| JP2008524167A (ja) | 2008-07-10 |
| BRPI0519148A2 (pt) | 2008-12-30 |
| KR20070094802A (ko) | 2007-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121857T1 (el) | Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα | |
| BR112022011072A2 (pt) | Intensificação de célula imune efetora derivada de ipsc usando compostos pequenos | |
| BR112012008624A2 (pt) | inibidores de tirosina quinase de bruton | |
| SV2006002513A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| WO2003089456A3 (en) | Peptide inhibitors of protein kinase c | |
| GB2453068A (en) | Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| TW200806317A (en) | Methods for reducing protein aggregation | |
| MX2009004665A (es) | Anticuerpos de anti-factor d humanizado. | |
| MA34519B1 (fr) | Anticorps anti-fap et procédés d'utilisation | |
| MX388981B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
| CY1110557T1 (el) | Αντισωματα ιντερλευκινης-10 | |
| BRPI0508085A (pt) | compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c | |
| BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| EA201000424A1 (ru) | Антитела к il-23 | |
| BR0112540A (pt) | Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c | |
| UY39740A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| BRPI0513477A (pt) | composições e processos de uso de proteìna 4 semelhante a angiotensina | |
| AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |